Samuel Kintz Sells 12,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $21.66, for a total value of $259,920.00. Following the sale, the chief executive officer now directly owns 1,075,525 shares in the company, valued at approximately $23,295,871.50. The sale was disclosed in a document filed with the SEC, which is available at this link.

Samuel Kintz also recently made the following trade(s):

• On Tuesday, May 28th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $23.18, for a total value of $278,160.00.
• On Thursday, April 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.89, for a total transaction of $202,680.00.
• On Thursday, April 11th, Samuel Kintz sold 47,709 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.04, for a total transaction of $1,194,633.36.

Enliven Therapeutics Trading Up 10.7 %

Shares of Enliven Therapeutics stock traded up $2.27 during mid-day trading on Thursday, reaching $23.45. 245,463 shares of the stock were exchanged, compared to its average volume of 256,961. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $26.00. The company has a market cap of $1.10 billion, a price-to-earnings ratio of -11.74 and a beta of 1.11. The firm has a 50-day simple moving average of $21.43 and a 200 day simple moving average of $17.57.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.04. On average, research analysts predict that Enliven Therapeutics, Inc. will post -2.26 EPS for the current fiscal year.

Institutional Investors Weigh In On Enliven Therapeutics

A number of large investors have recently bought and sold shares of ELVN. Janus Henderson Group PLC raised its position in Enliven Therapeutics by 74.8% in the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after purchasing an additional 305,397 shares during the last quarter. Baker BROS. Advisors LP bought a new position in shares of Enliven Therapeutics in the first quarter valued at about $2,020,000. Blackstone Inc. acquired a new position in Enliven Therapeutics during the 1st quarter worth about $443,000. EntryPoint Capital LLC acquired a new position in Enliven Therapeutics during the 1st quarter worth about $167,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Enliven Therapeutics in the 4th quarter valued at about $66,000. 95.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ELVN has been the subject of several recent research reports. Robert W. Baird assumed coverage on shares of Enliven Therapeutics in a research report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price target for the company. Mizuho started coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 target price for the company. Finally, Baird R W raised Enliven Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.